Is Quest Diagnostics Incorporated (DGX) overvalued? · P/E 22, rev $5.94B
Quest Diagnostics Incorporated (DGX) is a diagnostics & research company listed on US.
This page asks whether Quest Diagnostics Incorporated (DGX) looks expensive on cached numbers — not a short thesis.
Latest reported DGX revenue for 2026-06-30 was $5.94B. Net income was $572.0M. DGX currently screens at market cap $19.94B and trailing P/E 22.4.
DGX currently screens at market cap $19.94B and trailing P/E 22.4. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next DGX 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the DGX stock page for the full model, not this heading.
Not investment advice.